|Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.||
Accelerate drug approval
Goldberg, also a Manhattan Institute senior fellow, takes issue U.S. Rep. Edward Markey's criticism of a vital FDA program. Markey claimed that the FDA's accelerated approval process for life-threatening diseases is "broken" because, he said, companies marketing these drugs have completed only 50 percent of the studies they were required to complete. Goldberg responds that:
Mr. Markey uses fuzzy math to conclude that 50 percent of follow-up studies have not been completed. Actually, only 4 percent of the nearly 80 studies for drugs that have received accelerated approval are delayed, though they do take longer than anticipated in many cases.
|home spotlight commentary research events news about contact links archives|